To achieve this goal, the Institute is formed of a cross-disciplinary mix of clinicians and scientists that include physicians treating patients with novel gene therapies in the Mount Sinai Health System, biologists developing and testing new drugs and drug platforms, and data scientists working to identify causative agents of disease that can be targeted for therapy by building predictive models that better characterize disease.
[4] In January 2014, scientists from the institute’s Division of Psychiatric Genomics including Pamela Sklar published two papers in the journal Nature that explored the genetic complexity of schizophrenia.
[16][17][18] Institute faculty member Samir Parekh published results of a clinical trial in Blood Advances (2022) focused on second-line treatments for relapsed multiple myeloma patients.
[20][21] Also in 2022, Brian Brown's research published results of a study targeting solid tumors with chimeric antigen receptor (CAR)-T cell therapy, which had previously only been successful in blood cancers.
[23][24] Institute faculty member Ivan Marazzi's research team published a Nature paper in 2022 identifying the immune system's role in amyotrophic lateral sclerosis (ALS).
[29][30] Institute faculty Andrew Kasarskis, Michael Linderman, George Diaz, Ali Bashir, and Randi Zinberg taught the first class in which Mount Sinai medical students were able to fully sequence and analyze their own genomes.
[34][35] The Resilience Project aimed to scan the genomes of healthy people age 30 and older who contribute their DNA to the effort with an initial focus on 127 diseases.
[36][37] Based on an analysis of publicly available data from 600,000 human genomes, scientists involved in the Resilience Project estimated that one person in 15,000 has a mechanism protecting against disease-causing genetic variants.